PPARγ in human and mouse physiology

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1771, Issue 8, 2007, Pages 999-1013

  Heikkinen, Sami ^a,b   Auwerx, Johan ^a,c   Argmann, Carmen A ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c INSTITUT CLINIQUE DE LA SOURIS   (France)

Author keywords

Bone homeostasis; Human genetic variants; Longevity; Metabolism; Mouse models; PPAR

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN SENSITIZING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOSE TISSUE; ATHEROSCLEROSIS; B LYMPHOCYTE; BREAST EPITHELIUM; CANCER; CARDIOVASCULAR SYSTEM; DRUG EFFECT; ENDOTHELIUM CELL; GASTROINTESTINAL TRACT; GENETIC VARIABILITY; HOMEOSTASIS; HUMAN; LONGEVITY; MACROPHAGE; METABOLIC DISORDER; MORPHOGENESIS; MUTATION; NERVOUS TISSUE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; T LYMPHOCYTE; AMINO ACID SUBSTITUTION; ANIMAL; CARDIOVASCULAR FUNCTION; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; LUNG; MOUSE; NERVOUS SYSTEM FUNCTION; PANCREAS; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADIPOSE TISSUE; AMINO ACID SUBSTITUTION; ANIMALS; CARDIOVASCULAR PHYSIOLOGY; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION; HUMANS; KIDNEY; LUNG; MICE; MUSCLE, SKELETAL; NERVOUS SYSTEM PHYSIOLOGY; PANCREAS; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; VARIATION (GENETICS);

EID: 34547565190     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2007.03.006     Document Type: Review

References (157)

1. Rosen E.D., and Spiegelman B.M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276 (2001) 37731-37734
2. Knouff C., and Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr. Rev. 25 (2004) 899-918
3. Lehrke M., and Lazar M.A. The many faces of PPARgamma. Cell 123 (2005) 993-999
4. Zhu Y., Qi C., Korenberg J.R., Chen X.N., Noya D., Rao M.S., and Reddy J.K. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7921-7925
5. Zhu Y., Alvares K., Huang Q., Rao M.S., and Reddy J.K. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J. Biol. Chem. 268 (1993) 26817-26820
6. Tontonoz P., Hu E., Graves R.A., Budavari A.I., and Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8 (1994) 1224-1234
7. Greene M.E., Blumberg B., McBride O.W., Yi H.F., Kronquist K., Kwan K., Hsieh L., Greene G., and Nimer S.D. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 4 (1995) 281-299
8. Aperlo C., Pognonec P., Saladin R., Auwerx J., and Boulukos K.E. cDNA cloning and characterization of the transcriptional activities of the hamster peroxisome proliferator-activated receptor haPPAR gamma. Gene 162 (1995) 297-302
9. Fajas L., Auboeuf D., Raspe E., Schoonjans K., Lefebvre A.M., Saladin R., Najib J., Laville M., Fruchart J.C., Deeb S., Vidal-Puig A., Flier J., Briggs M.R., Staels B., Vidal H., and Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 272 (1997) 18779-18789
10. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., and Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68 (1992) 879-887
11. Werman A., Hollenberg A., Solanes G., Bjorbaek C., Vidal-Puig A.J., and Flier J.S. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and-2 isoforms and influence of insulin. J. Biol. Chem. 272 (1997) 20230-20235
12. Tontonoz P., Hu E., and Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79 (1994) 1147-1156
13. Vidal-Puig A.J., Considine R.V., Jimenez-Linan M., Werman A., Pories W.J., Caro J.F., and Flier J.S. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99 (1997) 2416-2422
14. Forman B.M., Chen J., and Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4312-4317
15. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., Devchand P., Wahli W., Willson T.M., Lenhard J.M., and Lehmann J.M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4318-4323
16. Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M.G., and Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11 (1997) 779-791
17. Picard F., and Auwerx J. PPAR(gamma) and glucose homeostasis. Annu. Rev. Nutr. 22 (2002) 167-197
18. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43 (2000) 527-550
19. Mann N.J. Paleolithic nutrition: what can we learn from the past?. Asia Pac. J. Clin. Nutr. 13 (2004) S17
20. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia 42 (1999) 1033-1049
21. Argmann C.A., Cock T.A., and Auwerx J. Peroxisome proliferator-activated receptor gamma: the more the merrier?. Eur. J. Clin. Invest. 35 (2005) 82-92
22. Yki-Järvinen H. Thiazolidinediones. N. Engl. J. Med. 351 (2004) 1106-1118
23. Schoonjans K., and Auwerx J. Thiazolidinediones: an update. Lancet 355 (2000) 1008-1010
24. Mudaliar S., Chang A.R., and Henry R.R. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr. Pract. 9 (2003) 406-416
25. Kawaguchi H., Akune T., Yamaguchi M., Ohba S., Ogata N., Chung U.I., Kubota N., Terauchi Y., Kadowaki T., and Nakamura K. Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. J. Bone Miner. Metab. 23 (2005) 275-279
26. Cock T.A., Back J., Elefteriou F., Karsenty G., Kastner P., Chan S., and Auwerx J. Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep. 5 (2004) 1007-1012
27. Lefebvre A.M., Chen I., Desreumaux P., Najib J., Fruchart J.C., Geboes K., Briggs M., Heyman R., and Auwerx J. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. 4 (1998) 1053-1057
28. Saez E., Tontonoz P., Nelson M.C., Alvarez J.G., Ming U.T., Baird S.M., Thomazy V.A., and Evans R.M. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat. Med. 4 (1998) 1058-1061
29. Norman R.A., Thompson D.B., Foroud T., Garvey W.T., Bennett P.H., Bogardus C., and Ravussin E. Genomewide search for genes influencing percent body fat in Pima Indians: suggestive linkage at chromosome 11q21-q22. Pima Diabetes Gene Group. Am. J. Hum. Genet. 60 (1997) 166-173
30. Altshuler D., Hirschhorn J.N., Klannemark M., Lindgren C.M., Vohl M.C., Nemesh J., Lane C.R., Schaffner S.F., Bolk S., Brewer C., Tuomi T., Gaudet D., Hudson T.J., Daly M., Groop L., and Lander E.S. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26 (2000) 76-80
31. Deeb S.S., Fajas L., Nemoto M., Pihlajamäki J., Mykkänen L., Kuusisto J., Laakso M., Fujimoto W., and Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20 (1998) 284-287
32. Masugi J., Tamori Y., Mori H., Koike T., and Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem. Biophys. Res. Commun. 268 (2000) 178-182
33. Florez J.C., Hirschhorn J., and Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu. Rev. Genomics Hum. Genet. 4 (2003) 257-291
34. Masud S., and Ye S. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J. Med. Genet. 40 (2003) 773-780
35. Tönjes A., Scholz M., Loeffler M., and Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor {gamma} with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 29 (2006) 2489-2497
36. Ek J., Urhammer S.A., Sorensen T.I., Andersen T., Auwerx J., and Pedersen O. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 42 (1999) 892-895
37. Vänttinen M., Nuutila P., Pihlajamäki J., Hallsten K., Virtanen K.A., Lautamäki R., Peltoniemi P., Kemppainen J., Takala T., Viljanen A.P., Knuuti J., and Laakso M. The effect of the Ala12 allele of the peroxisome proliferator-activated receptor-gamma2 gene on skeletal muscle glucose uptake depends on obesity: a positron emission tomography study. J. Clin. Endocrinol. Metab. 90 (2005) 4249-4254
38. Soriguer F., Morcillo S., Cardona F., Rojo-Martinez G., de la Cruz Almaraz M., Ruiz de Adana Mde L., Olveira G., Tinahones F., and Esteva I. Pro12Ala polymorphism of the PPARG2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid. J. Nutr. 136 (2006) 2325-2330
39. Franks P.W., Luan J., Browne P.O., Harding A.H., O'Rahilly S., Chatterjee V.K., and Wareham N.J. Does peroxisome proliferator-activated receptor gamma genotype (Pro12ala) modify the association of physical activity and dietary fat with fasting insulin level?. Metabolism 53 (2004) 11-16
40. Luan J., Browne P.O., Harding A.H., Halsall D.J., O'Rahilly S., Chatterjee V.K., and Wareham N.J. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 50 (2001) 686-689
41. Al-Shali K.Z., House A.A., Hanley A.J., Khan H.M., Harris S.B., Zinman B., Mamakeesick M., Fenster A., Spence J.D., and Hegele R.A. Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis. Stroke 35 (2004) 2036-2040
42. Barbieri M., Bonafe M., Rizzo M.R., Ragno E., Olivieri F., Marchegiani F., Franceschi C., and Paolisso G. Gender specific association of genetic variation in peroxisome proliferator-activated receptor (PPAR)gamma-2 with longevity. Exp. Gerontol. 39 (2004) 1095-1100
43. Ridker P.M., Cook N.R., Cheng S., Erlich H.A., Lindpaintner K., Plutzky J., and Zee R.Y. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 859-863
44. Temelkova-Kurktschiev T., Hanefeld M., Chinetti G., Zawadzki C., Haulon S., Kubaszek A., Koehler C., Leonhardt W., Staels B., and Laakso M. Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J. Clin. Endocrinol. Metab. 89 (2004) 4238-4242
45. Ylihärsilä H., Eriksson J.G., Forsen T., Laakso M., Uusitupa M., Osmond C., and Barker D.J. Interactions between peroxisome proliferator-activated receptor-gamma 2 gene polymorphisms and size at birth on blood pressure and the use of antihypertensive medication. J. Hypertens. 22 (2004) 1283-1287
46. Zmuda J.M., Modugno F., Weissfeld J.L., Cauley J.A., Trump D.L., Moffett S.P., and Ferrell R.E. Peroxisome proliferator-activated receptor-gamma polymorphism, body mass and prostate cancer risk: evidence for gene-environment interaction. Oncology 70 (2006) 185-189
47. Pihlajamäki J., Vanhala M., Vanhala P., and Laakso M. The Pro12Ala polymorphism of the PPAR gamma 2 gene regulates weight from birth to adulthood. Obes. Res. 12 (2004) 187-190
48. Yaffe K., Kanaya A.M., Lindquist K., Hsueh W.C., Cummings S.R., Beamer B., Newman A., Rosano C., Li R., and Harris T. PPAR-gamma Pro12Ala genotype and risk of cognitive decline in elders. Neurobiol. Aging (2006) 10.1016/j.neurobiolaging.2006.09.010
49. Semple R.K., Chatterjee V.K., and O'Rahilly S. PPAR gamma and human metabolic disease. J. Clin. Invest. 116 (2006) 581-589
50. Damcott C.M., Moffett S.P., Feingold E., Barmada M.M., Marshall J.A., Hamman R.F., and Ferrell R.E. Genetic variation in fatty acid-binding protein-4 and peroxisome proliferator-activated receptor gamma interactively influence insulin sensitivity and body composition in males. Metabolism 53 (2004) 303-309
51. Weedon M.N., McCarthy M.I., Hitman G., Walker M., Groves C.J., Zeggini E., Rayner N.W., Shields B., Owen K.R., Hattersley A.T., and Frayling T.M. Combining information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med. 3 (2006)
52. Cecil J.E., Fischer B., Doney A.S., Hetherington M., Watt P., Wrieden W., Bolton-Smith C., and Palmer C.N. The Pro12Ala and C-681G variants of the PPARG locus are associated with opposing growth phenotypes in young schoolchildren. Diabetologia 48 (2005) 1496-1502
53. Doney A.S., Fischer B., Cecil J.E., Boylan K., McGuigan F.E., Ralston S.H., Morris A.D., and Palmer C.N. Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia 47 (2004) 555-558
54. Savage D.B., Agostini M., Barroso I., Gurnell M., Luan J., Meirhaeghe A., Harding A.H., Ihrke G., Rajanayagam O., Soos M.A., George S., Berger D., Thomas E.L., Bell J.D., Meeran K., Ross R.J., Vidal-Puig A., Wareham N.J., O'Rahilly S., Chatterjee V.K., and Schafer A.J. Digenic inheritance of severe insulin resistance in a human pedigree. Nat. Genet. 31 (2002) 379-384
55. Barroso I., Gurnell M., Crowley V.E., Agostini M., Schwabe J.W., Soos M.A., Maslen G.L., Williams T.D., Lewis H., Schafer A.J., Chatterjee V.K., and O'Rahilly S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402 (1999) 880-883
56. Agarwal A.K., and Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J. Clin. Endocrinol. Metab. 87 (2002) 408-411
57. Savage D.B., Tan G.D., Acerini C.L., Jebb S.A., Agostini M., Gurnell M., Williams R.L., Umpleby A.M., Thomas E.L., Bell J.D., Dixon A.K., Dunne F., Boiani R., Cinti S., Vidal-Puig A., Karpe F., Chatterjee V.K., and O'Rahilly S. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 52 (2003) 910-917
58. Agostini M., Gurnell M., Savage D.B., Wood E.M., Smith A.G., Rajanayagam O., Garnes K.T., Levinson S.H., Xu H.E., Schwabe J.W., Willson T.M., O'Rahilly S., and Chatterjee V.K. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma. Endocrinology 145 (2004) 1527-1538
59. Agostini M., Schoenmakers E., Mitchell C., Szatmari I., Savage D., Smith A., Rajanayagam O., Semple R., Luan J., Bath L., Zalin A., Labib M., Kumar S., Simpson H., Blom D., Marais D., Schwabe J., Barroso I., Trembath R., Wareham N., Nagy L., Gurnell M., O'Rahilly S., and Chatterjee K. Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metab. 4 (2006) 303-311
60. Ristow M., Muller-Wieland D., Pfeiffer A., Krone W., and Kahn C.R. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N. Engl. J. Med. 339 (1998) 953-959
61. Hegele R.A., Cao H., Frankowski C., Mathews S.T., and Leff T. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51 (2002) 3586-3590
62. Francis G.A., Li G., Casey R., Wang J., Cao H., Leff T., and Hegele R.A. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med. Genet. 7 (2006) 3
63. Al-Shali K., Cao H., Knoers N., Hermus A.R., Tack C.J., and Hegele R.A. A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy. J. Clin. Endocrinol. Metab. 89 (2004) 5655-5660
64. Meirhaeghe A., Fajas L., Helbecque N., Cottel D., Lebel P., Dallongeville J., Deeb S., Auwerx J., and Amouyel P. A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum. Mol. Genet. 7 (1998) 435-440
65. Ogawa S., Urano T., Hosoi T., Miyao M., Hoshino S., Fujita M., Shiraki M., Orimo H., Ouchi Y., and Inoue S. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem. Biophys. Res. Commun. 260 (1999) 122-126
66. Valve R., Sivenius K., Miettinen R., Pihlajamäki J., Rissanen A., Deeb S.S., Auwerx J., Uusitupa M., and Laakso M. Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J. Clin. Endocrinol. Metab. 84 (1999) 3708-3712
67. Doney A.S., Fischer B., Leese G., Morris A.D., and Palmer C.N. Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2403-2407
68. Rhee E.J., Oh K.W., Lee W.Y., Kim S.Y., Oh E.S., Baek K.H., Kang M.I., and Kim S.W. Effects of two common polymorphisms of peroxisome proliferator-activated receptor-gamma gene on metabolic syndrome. Arch. Med. Res. 37 (2006) 86-94
69. Muller Y.L., Bogardus C., Beamer B.A., Shuldiner A.R., and Baier L.J. A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes 52 (2003) 1864-1871
70. Meirhaeghe A., Fajas L., Gouilleux F., Cottel D., Helbecque N., Auwerx J., and Amouyel P. A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 289-294
71. Meirhaeghe A., Tanck M.W., Fajas L., Janot C., Helbecque N., Cottel D., Auwerx J., Amouyel P., and Dallongeville J. Study of a new PPARgamma2 promoter polymorphism and haplotype analysis in a French population. Mol. Genet. Metab. 85 (2005) 140-148
72. Wei Q., Jacobs Jr. D.R., Schreiner P.J., Siscovick D.S., Steffes M.W., and Fornage M. Patterns of association between PPARgamma genetic variation and indices of adiposity and insulin action in African-Americans and whites: the CARDIA Study. J. Mol. Med. 84 (2006) 955-965
73. Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., Koder A., and Evans R.M. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 4 (1999) 585-595
74. Rosen E.D., Sarraf P., Troy A.E., Bradwin G., Moore K., Milstone D.S., Spiegelman B.M., and Mortensen R.M. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4 (1999) 611-617
75. Kubota N., Terauchi Y., Miki H., Tamemoto H., Yamauchi T., Komeda K., Satoh S., Nakano R., Ishii C., Sugiyama T., Eto K., Tsubamoto Y., Okuno A., Murakami K., Sekihara H., Hasegawa G., Naito M., Toyoshima Y., Tanaka S., Shiota K., Kitamura T., Fujita T., Ezaki O., Aizawa S., Kadowaki T., et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4 (1999) 597-609
76. Miles P.D., Barak Y., Evans R.M., and Olefsky J.M. Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding. Am. J. Physiol.: Endocrinol. Metab. 284 (2003) E618-E626
77. Jones J.R., Shelton K.D., Guan Y., Breyer M.D., and Magnuson M.A. Generation and functional confirmation of a conditional null PPARgamma allele in mice. Genesis 32 (2002) 134-137
78. Koutnikova H., Cock T.A., Watanabe M., Houten S.M., Champy M.F., Dierich A., and Auwerx J. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14457-14462
79. He W., Barak Y., Hevener A., Olson P., Liao D., Le J., Nelson M., Ong E., Olefsky J.M., and Evans R.M. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15712-15717
80. Jones J.R., Barrick C., Kim K.A., Lindner J., Blondeau B., Fujimoto Y., Shiota M., Kesterson R.A., Kahn B.B., and Magnuson M.A. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 6207-6212
81. Imai T., Takakuwa R., Marchand S., Dentz E., Bornert J.M., Messaddeq N., Wendling O., Mark M., Desvergne B., Wahli W., Chambon P., and Metzger D. Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4543-4547
82. Zhang J., Fu M., Cui T., Xiong C., Xu K., Zhong W., Xiao Y., Floyd D., Liang J., Li E., Song Q., and Chen Y.E. Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10703-10708
83. Medina-Gomez G., Virtue S., Lelliott C., Boiani R., Campbell M., Christodoulides C., Perrin C., Jimenez-Linan M., Blount M., Dixon J., Zahn D., Thresher R.R., Aparicio S., Carlton M., Colledge W.H., Kettunen M.I., Seppanen-Laakso T., Sethi J.K., O'Rahilly S., Brindle K., Cinti S., Oresic M., Burcelin R., and Vidal-Puig A. The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform. Diabetes 54 (2005) 1706-1716
84. Norris A.W., Chen L., Fisher S.J., Szanto I., Ristow M., Jozsi A.C., Hirshman M.F., Rosen E.D., Goodyear L.J., Gonzalez F.J., Spiegelman B.M., and Kahn C.R. Muscle-specific PPAR{gamma}-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. 112 (2003) 608-618
85. Hevener A.L., He W., Barak Y., Le J., Bandyopadhyay G., Olson P., Wilkes J., Evans R.M., and Olefsky J. Muscle-specific Pparg deletion causes insulin resistance. Nat. Med. 9 (2003) 1491-1497
86. Gavrilova O., Haluzik M., Matsusue K., Cutson J.J., Johnson L., Dietz K.R., Nicol C.J., Vinson C., Gonzalez F.J., and Reitman M.L. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278 (2003) 34268-34276
87. Matsusue K., Haluzik M., Lambert G., Yim S.H., Gavrilova O., Ward J.M., Brewer Jr. B., Reitman M.L., and Gonzalez F.J. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. 111 (2003) 737-747
88. Singh J., Verma N.K., Kansagra S.M., Kate B.N., and Dey C.S. Altered PPARgamma expression inhibits myogenic differentiation in C2C12 skeletal muscle cells. Mol. Cell. Biochem. 294 (2007) 163-171
89. Yu S., Matsusue K., Kashireddy P., Cao W.Q., Yeldandi V., Yeldandi A.V., Rao M.S., Gonzalez F.J., and Reddy J.K. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J. Biol. Chem. 278 (2003) 498-505
90. Yu S., Viswakarma N., Batra S.K., Sambasiva Rao M., and Reddy J.K. Identification of promethin and PGLP as two novel up-regulated genes in PPARgamma1-induced adipogenic mouse liver. Biochimie 86 (2004) 743-761
91. Tanaka T., Masuzaki H., Ebihara K., Ogawa Y., Yasue S., Yukioka H., Chusho H., Miyanaga F., Miyazawa T., Fujimoto M., Kusakabe T., Kobayashi N., Hayashi T., Hosoda K., and Nakao K. Transgenic expression of mutant peroxisome proliferator-activated receptor gamma in liver precipitates fasting-induced steatosis but protects against high-fat diet-induced steatosis in mice. Metabolism 54 (2005) 1490-1498
92. Welters H.J., McBain S.C., Tadayyon M., Scarpello J.H., Smith S.A., and Morgan N.G. Expression and functional activity of PPARgamma in pancreatic beta cells. Br. J. Pharmacol. 142 (2004) 1162-1170
93. Dubois M., Pattou F., Kerr-Conte J., Gmyr V., Vandewalle B., Desreumaux P., Auwerx J., Schoonjans K., and Lefebvre J. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 43 (2000) 1165-1169
94. Rosen E.D., Kulkarni R.N., Sarraf P., Ozcan U., Okada T., Hsu C.H., Eisenman D., Magnuson M.A., Gonzalez F.J., Kahn C.R., and Spiegelman B.M. Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol. Cell. Biol. 23 (2003) 7222-7229
95. Matsui J., Terauchi Y., Kubota N., Takamoto I., Eto K., Yamashita T., Komeda K., Yamauchi T., Kamon J., Kita S., Noda M., and Kadowaki T. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet. Diabetes 53 (2004) 2844-2854
96. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., Liao D., Nagy L., Edwards P.A., Curtiss L.K., Evans R.M., and Tontonoz P. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 7 (2001) 161-171
97. Babaev V.R., Yancey P.G., Ryzhov S.V., Kon V., Breyer M.D., Magnuson M.A., Fazio S., and Linton M.F. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1647-1653
98. Akiyama T.E., Sakai S., Lambert G., Nicol C.J., Matsusue K., Pimprale S., Lee Y.H., Ricote M., Glass C.K., Brewer Jr. H.B., and Gonzalez F.J. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell. Biol. 22 (2002) 2607-2619
99. de Luca C., and Olefsky J.M. Stressed out about obesity and insulin resistance. Nat. Med. 12 (2006) 41-42
100. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
101. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112 (2003) 1796-1808
102. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., and Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112 (2003) 1821-1830
103. Nicol C.J., Adachi M., Akiyama T.E., and Gonzalez F.J. PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am. J. Hypertens. 18 (2005) 549-556
104. Asakawa M., Takano H., Nagai T., Uozumi H., Hasegawa H., Kubota N., Saito T., Masuda Y., Kadowaki T., and Komuro I. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105 (2002) 1240-1246
105. Duan S.Z., Ivashchenko C.Y., Russell M.W., Milstone D.S., and Mortensen R.M. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ. Res. 97 (2005) 372-379
106. Zhang H., Zhang A., Kohan D.E., Nelson R.D., Gonzalez F.J., and Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9406-9411
107. Guan Y., Hao C., Cha D.R., Rao R., Lu W., Kohan D.E., Magnuson M.A., Redha R., Zhang Y., and Breyer M.D. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med. 11 (2005) 861-866
108. Wang A.C., Dai X., Luu B., and Conrad D.J. Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am. J. Respir. Cell Mol. Biol. 24 (2001) 688-693
109. Simon D.M., Arikan M.C., Srisuma S., Bhattacharya S., Tsai L.W., Ingenito E.P., Gonzalez F., Shapiro S.D., and Mariani T.J. Epithelial cell PPAR[gamma] contributes to normal lung maturation. FASEB J. 20 (2006) 1507-1509
110. Woerly G., Honda K., Loyens M., Papin J.P., Auwerx J., Staels B., Capron M., and Dombrowicz D. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J. Exp. Med. 198 (2003) 411-421
111. Delayre-Orthez C., Becker J., Guenon I., Lagente V., Auwerx J., Frossard N., and Pons F. PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse. Respir. Res. 6 (2005) 91
112. Cui Y., Miyoshi K., Claudio E., Siebenlist U.K., Gonzalez F.J., Flaws J., Wagner K.U., and Hennighausen L. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J. Biol. Chem. 277 (2002) 17830-17835
113. Schaiff W.T., Barak Y., and Sadovsky Y. The pleiotropic function of PPAR gamma in the placenta. Mol. Cell. Endocrinol. 249 (2006) 10-15
114. Aquila S., Bonofiglio D., Gentile M., Middea E., Gabriele S., Belmonte M., Catalano S., Pellegrino M., and Ando S. Peroxisome proliferator-activated receptor (PPAR)gamma is expressed by human spermatozoa: its potential role on the sperm physiology. J. Cell. Physiol. 209 (2006) 977-986
115. Lefebvre M., Paulweber B., Fajas L., Woods J., McCrary C., Colombel J.F., Najib J., Fruchart J.C., Datz C., Vidal H., Desreumaux P., and Auwerx J. Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J. Endocrinol. 162 (1999) 331-340
116. Girnun G.D., Smith W.M., Drori S., Sarraf P., Mueller E., Eng C., Nambiar P., Rosenberg D.W., Bronson R.T., Edelmann W., Kucherlapati R., Gonzalez F.J., and Spiegelman B.M. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13771-13776
117. McAlpine C.A., Barak Y., Matise I., and Cormier R.T. Intestinal-specific PPARgamma deficiency enhances tumorigenesis in Apc(Min/+) mice. Int. J. Cancer 119 (2006) 2339-2346
118. Fajas L., Egler V., Reiter R., Miard S., Lefebvre A.M., and Auwerx J. PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner. Oncogene 22 (2003) 4186-4193
119. Adachi M., Kurotani R., Morimura K., Shah Y., Sanford M., Madison B.B., Gumucio D.L., Marin H.E., Peters J.M., Young H.A., and Gonzalez F.J. Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 55 (2006) 1104-1113
120. Desreumaux P., Dubuquoy L., Nutten S., Peuchmaur M., Englaro W., Schoonjans K., Derijard B., Desvergne B., Wahli W., Chambon P., Leibowitz M.D., Colombel J.F., and Auwerx J. Attenuation of colon inflammation through activators of the retinoid × receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J. Exp. Med. 193 (2001) 827-838
121. Rousseaux C., Lefebvre B., Dubuquoy L., Lefebvre P., Romano O., Auwerx J., Metzger D., Wahli W., Desvergne B., Naccari G.C., Chavatte P., Farce A., Bulois P., Cortot A., Colombel J.F., and Desreumaux P. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J. Exp. Med. 201 (2005) 1205-1215
122. Welch J.S., Ricote M., Akiyama T.E., Gonzalez F.J., and Glass C.K. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6712-6717
123. Mao-Qiang M., Fowler A.J., Schmuth M., Lau P., Chang S., Brown B.E., Moser A.H., Michalik L., Desvergne B., Wahli W., Li M., Metzger D., Chambon P.H., Elias P.M., and Feingold K.R. Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J. Invest. Dermatol. 123 (2004) 305-312
124. Wada K., Nakajima A., Katayama K., Kudo C., Shibuya A., Kubota N., Terauchi Y., Tachibana M., Miyoshi H., Kamisaki Y., Mayumi T., Kadowaki T., and Blumberg R.S. Peroxisome proliferator-activated receptor gamma-mediated regulation of neural stem cell proliferation and differentiation. J. Biol. Chem. 281 (2006) 12673-12681
125. Raikwar H.P., Muthian G., Rajasingh J., Johnson C.N., and Bright J.J. PPARgamma antagonists reverse the inhibition of neural antigen-specific Th(1) response and experimental allergic encephalomyelitis by Ciglitazone and 15-Deoxy-Delta(12,14)-Prostaglandin J(2). J. Neuroimmunol. 178 (2006) 76-86
126. Natarajan C., Muthian G., Barak Y., Evans R.M., and Bright J.J. Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J. Immunol. 171 (2003) 5743-5750
127. Karsenty G., and Wagner E.F. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2 (2002) 389-406
128. Rhee E.J., Oh K.W., Lee W.Y., Kim S.Y., Oh E.S., Baek K.H., Kang M.I., and Kim S.W. The effects of C161 → T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. Am. J. Obstet. Gynecol. 192 (2005) 1087-1093
129. Rzonca S.O., Suva L.J., Gaddy D., Montague D.C., and Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145 (2004) 401-406
130. Klein R.F., Allard J., Avnur Z., Nikolcheva T., Rotstein D., Carlos A.S., Shea M., Waters R.V., Belknap J.K., Peltz G., and Orwoll E.S. Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 303 (2004) 229-232
131. Ali A.A., Weinstein R.S., Stewart S.A., Parfitt A.M., Manolagas S.C., and Jilka R.L. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146 (2005) 1226-1235
132. Akune T., Ohba S., Kamekura S., Yamaguchi M., Chung U.I., Kubota N., Terauchi Y., Harada Y., Azuma Y., Nakamura K., Kadowaki T., and Kawaguchi H. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest. 113 (2004) 846-855
133. Reue K., and Phan J. Metabolic consequences of lipodystrophy in mouse models. Curr. Opin. Clin. Nutr. Metab. Care 9 (2006) 436-441
134. Garg A. Acquired and inherited lipodystrophies. N. Engl. J. Med. 350 (2004) 1220-1234
135. Koubova J., and Guarente L. How does calorie restriction work?. Genes Dev. 17 (2003) 313-321
136. Wolf G. Calorie restriction increases life span: a molecular mechanism. Nutr. Rev. 64 (2006) 89-92
137. Blüher M., Kahn B.B., and Kahn C.R. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299 (2003) 572-574
138. Barthel A., Schmoll D., and Unterman T.G. FoxO proteins in insulin action and metabolism. Trends Endocrinol. Metab. 16 (2005) 183-189
139. Giannakou M.E., Goss M., Junger M.A., Hafen E., Leevers S.J., and Partridge L. Long-lived Drosophila with overexpressed dFOXO in adult fat body. Science 305 (2004) 361
140. Hwangbo D.S., Gershman B., Tu M.P., Palmer M., and Tatar M. Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. Nature 429 (2004) 562-566
141. Libina N., Berman J.R., and Kenyon C. Tissue-specific activities of C. elegans DAF-16 in the regulation of lifespan. Cell 115 (2003) 489-502
142. Picard F., Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado De Oliveira R., Leid M., McBurney M.W., and Guarente L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429 (2004) 771-776
143. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., and Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127 (2006) 1109-1122
144. Rangwala S.M., Rhoades B., Shapiro J.S., Rich A.S., Kim J.K., Shulman G.I., Kaestner K.H., and Lazar M.A. Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev. Cell 5 (2003) 657-663
145. Park Y., Freedman B.D., Lee E.J., Park S., and Jameson J.L. A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells. Diabetologia 46 (2003) 365-377
146. Freedman B.D., Lee E.J., Park Y., and Jameson J.L. A dominant negative peroxisome proliferator-activated receptor-gamma knock-in mouse exhibits features of the metabolic syndrome. J. Biol. Chem. 280 (2005) 17118-17125
147. Gray S.L., Dalla Nora E., Grosse J., Manieri M., Stoeger T., Medina-Gomez G., Burling K., Wattler S., Russ A., Yeo G.S., Chatterjee V.K., O'Rahilly S., Voshol P.J., Cinti S., and Vidal-Puig A. Leptin Deficiency Unmasks the Deleterious Effects of Impaired Peroxisome Proliferator-Activated Receptor {gamma} Function (P465L PPAR{gamma}) in Mice. Diabetes 55 (2006) 2669-2677
148. Tsai Y.S., Kim H.J., Takahashi N., Kim H.S., Hagaman J.R., Kim J.K., and Maeda N. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma. J. Clin. Invest. 114 (2004) 240-249
149. Gray S.L., Dalla Nora E., Backlund E.C., Manieri M., Virtue S., Noland R.C., O'Rahilly S., Cortright R.N., Cinti S., Cannon B., and Vidal-Puig A. Decreased brown adipocyte recruitment and thermogenic capacity in mice with impaired peroxisome proliferator-activated receptor (P465L PPARgamma) function. Endocrinology 147 (2006) 5708-5714
150. Hegele R.A., and Leff T. Unbuckling lipodystrophy from insulin resistance and hypertension. J. Clin. Invest. 114 (2004) 163-165
151. Ryan M.J., Didion S.P., Mathur S., Faraci F.M., and Sigmund C.D. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43 (2004) 661-666
152. Dobrian A.D., Schriver S.D., Khraibi A.A., and Prewitt R.L. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 43 (2004) 48-56
153. Blaschke F., Takata Y., Caglayan E., Law R.E., and Hsueh W.A. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 28-40
154. Rocchi S., Picard F., Vamecq J., Gelman L., Potier N., Zeyer D., Dubuquoy L., Bac P., Champy M.F., Plunket K.D., Leesnitzer L.M., Blanchard S.G., Desreumaux P., Moras D., Renaud J.P., and Auwerx J. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell 8 (2001) 737-747
155. Tenenbaum A., Motro M., Fisman E.Z., Schwammenthal E., Adler Y., Goldenberg I., Leor J., Boyko V., Mandelzweig L., and Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109 (2004) 2197-2202
156. Fiévet C., Fruchart J.C., and Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr. Opin. Pharmacol. 6 (2006) 606-614
157. Xu Y., Etgen G.J., Broderick C.L., Canada E., Gonzalez I., Lamar J., Montrose-Rafizadeh C., Oldham B.A., Osborne J.J., Xie C., Shi Q., Winneroski L.L., York J., Yumibe N., Zink R., and Mantlo N. Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile. J. Med. Chem. 49 (2006) 5649-5652